semaglutide.dosing How to Use Ozempic® Pen Tirzepatide and Semaglutide key differences,

Description

These findings are unusual in a patient in her 40s, but could be due to hypovolemia from semaglutide

Study: TripleHormone Receptor Agonist Retatrutide for Obesity (Phase 2 Trial, NEJM) Drug: Retatrutide a triple agonist (GLP-1, GIP, and glucagon receptors) Key Findings: Up to 28.7% mean weight loss at higher doses Marked improvements in insulin sensitivity and cardiometabolic risk factors Weight loss approaching outcomes seen with bariatric surgery, without surgery What makes Retatrutide unique is its triple-hormone mechanism, simultaneously targeting appetite regulation, energy expenditure, and glucose metabolism

two patients had only obesity

Research links processed food intake to higher body weights and weight gain

Inform them about: Your IBS subtype (constipation, diarrhoea, or mixed) Current symptom severity and frequency Existing IBS treatments and their effectiveness Previous responses to medications affecting gut motility Impact of IBS on your quality of life This information helps clinicians make informed decisions about whether GLP-1 therapy is appropriate and how to monitor you effectively